thumbnail image

UE LifeSciences

  • Innovations 
    • iBreastExam
    • cervAIcal
  • About Us 
    • Journey
    • Team
    • Newsletter
  • Contact Us
  • …  
    • Innovations 
      • iBreastExam
      • cervAIcal
    • About Us 
      • Journey
      • Team
      • Newsletter
    • Contact Us
Stay Abreast

UE LifeSciences

  • Innovations 
    • iBreastExam
    • cervAIcal
  • About Us 
    • Journey
    • Team
    • Newsletter
  • Contact Us
  • …  
    • Innovations 
      • iBreastExam
      • cervAIcal
    • About Us 
      • Journey
      • Team
      • Newsletter
    • Contact Us
Stay Abreast
  • Making Breast Exams Quick & Painless

    radiation-free and easy, for women everywhere

    US Distribution Partnership Announcement

    Announced Jan, 2022

     

    2022 Global Women's HealthTech Award from The World Bank, IFC and CTA

    Jan 2022

     

    Innovative Health Technology Recognized by the World Health Organization

     

    2021 Thought Leader - ACOG TV 

    ACOG 2021 American College of Obstetricians and Gynecologists Annual Meeting

    $1.7M in Global Grant Awards in Innovation, Global Health & Oncology categories

    Now available in:

     

    United States

    Mexico

    Colombia

    Egypt

    Botswana

    India

    Malaysia

    Indonesia

    Nepal

    Oman

     

  • Validations & Publications by Global Experts & Clinical Advisors

     

    Our Clinical Advisory Team consists of globally recognized experts and key opinion leaders in breast cancer control and treatment. 7,500 women have been enrolled in multiple investigator-led clinical validations with publications in leading international, peer-reviewed journals:

    In conclusion, this study demonstrated excellent negative predictive value of iBE and agreement between iBE and CBE as triage tests for the detection of clinically relevant breast lesions.
    iBreastExam identified 15 women with a correlating BIRAD 4 score, of which 3 were confirmed as early-stage breast cancers (Stage IIA, IA and DCIS), none with palpable abnormality on clinical breast examination.
     
    97% of the participants reported the test as acceptable and recommendable to relatives and 98% expressed an interest to have iBreastExam made available at local Public Health Centers.
    This validation study demonstrated excellent sensitivity of iBE for the identification of clinically significant lesions in patients presenting for diagnostic imaging.
    Identified abnormalities in all 39 patients who presented with breast abnormalities and did not demonstrate any false negatives that would prevent the patients from additional evaluation, which makes it a good prescreening tool.
    iBreastExam demonstrated significantly (23%) higher sensitivity and moderately (9%) higher specificity to detect breast lesions as compared to CBE. Lower FP rates compared to CBE reduces the pool of women requiring further diagnostic follow-up. iBreastExam requires minimal training and provides objective breast examination with digital documentation
  • Product Literature

    Download Brochure

    DOWNLOAD

Home

Journey

Team

Newsletter

+1.267.225.0453

info@UELifeSciences.com

iBreastExam

cervAIcal

UE LifeSciences Inc. Copyright © 2021 | Terms & Conditions

    Invest
    News
    Call
    Email
All Posts
×
Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
Learn More